76318-50-8

Basic information

• Product Name: METHYL 3,5-DIIODO-L-TYROSINATE
• Synonyms: L-TYROSINE, 3,5-DIIODO-, METHYL ESTER;METHYL 3,5-DIIODO-L-TYROSINATE;3,5-DIIODO-L-TYROSINE METHYL ESTER;Methyl 3,5-diiodo-L-tyrosinate 98%;(S)-Methyl 2-aMino-3-(4-hydroxy-3,5-diiodophenyl)propanoate
• CAS NO: 76318-50-8
• Molecular Formula: C₁₀H₁₁I₂NO₃
• Molecular Weight: 447.01
• Product Categories: Chiral Compound
• Mol File: 76318-50-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 373.6oC at 760 mmHg
• Flash Point: 179.8oC
• Appearance: /
• Density: 2.176g/cm3
• Vapor Pressure: 4.11E-06mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: 2-8°C
• CAS DataBase Reference: METHYL 3,5-DIIODO-L-TYROSINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3,5-DIIODO-L-TYROSINATE(76318-50-8)
• EPA Substance Registry System: METHYL 3,5-DIIODO-L-TYROSINATE(76318-50-8)

Safety Data

• Hazardous Substances Data: 76318-50-8(Hazardous Substances Data)

Usage

General Description

Methyl 3,5-diiodo-L-tyrosinate is a chemical compound containing the methyl ester of 3,5-diiodo-L-tyrosine. It is primarily used as an intermediate in the synthesis of pharmaceuticals and research chemicals. METHYL 3,5-DIIODO-L-TYROSINATE has potential applications in medical research and drug discovery due to its ability to modulate biological processes and serve as a building block for more complex molecules. Its unique structure and functional groups make it a valuable component in the development of new drugs and treatments. However, it is important to handle this compound with caution and adhere to proper safety protocols due to its potential reactivity and toxicity.

InChI:InChI=1/C10H11I2NO3/c1-16-10(15)8(13)4-5-2-6(11)9(14)7(12)3-5/h2-3,8,14H,4,13H2,1H3/t8-/m1/s1

Upstream product

• 67-56-1 methanol 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 1080-06-4 L-Tyr-OMe 
• 60-18-4 L-tyrosine 

Downstream Products

• 56460-41-4 3.5-diiodo-N-acetyl-L-tyrosine methyl ester 
• 95253-83-1 3.5-diiodo-N-(N-benzyloxycarbonyl-α-L-glutamyl)-L-tyrosine 
• 108890-90-0 K-13 
• 120363-27-1 Methyl (9S,12S,15S)-15-(acetylamino)-4-hydroxy-12-<(4-hydroxyphenyl)methyl>-11,14-dioxo-2-oxa-10,13-diazatricyclo<15.2.2.1^3,7>docosa-3,5,7(22),17,19,20-hexaene-9-carboxylate 
• 123418-36-0 (9S,12S,15S)-9-Acetylamino-4-hydroxy-12-(4-hydroxy-benzyl)-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid 
• 123418-35-9 (9S,12S,15S)-9-Acetylamino-4-hydroxy-12-(4-hydroxy-benzyl)-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid methyl ester 
• 123418-37-1 (S)-2-[(S)-2-Amino-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-hydroxy-3,5-diiodo-phenyl)-propionic acid methyl ester; hydrochloride 
• 123418-38-2 N-acetyl-3,5-dichloro-L-tyrosyl-O-benzyl-L-tyrosyl-3,5-diiodo-L-tyrosinemethyl ester 
• 123418-39-3 (9S,12S,15S)-15-Acetylamino-12-(4-benzyloxy-benzyl)-19,20-dichloro-4-hydroxy-5-iodo-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3⁽²²⁾,4,6,17⁽²¹⁾,18-hexaene-9-carboxylic acid methyl ester 
• 123418-40-6 (9S,12S,15S)-9-Acetylamino-12-(4-benzyloxy-benzyl)-5-chloro-4-hydroxy-19,20-diiodo-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid methyl ester 
• 128781-80-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-diiodophenyl)propanoate 

Relevant articles and documents

A novel class of tyrosine derivatives as dual 5-LOX and COX-2/mPGES1 inhibitors with PGE2 mediated anticancer properties

Leukotriene and prostaglandin pathways are controlled by the enzymes, LOX and COX/mPGES1 respectively and are responsible for inflammatory responses. PGE2, produced by mPGES1, leads to the progression of inflammation as well as cancer. A series of 19 novel tyrosine derivatives are synthesized, characterized and tested against 5-LOX, in vitro, and production of PGE2, in HeLa cells. 6b-v and 6c-i, are found to possess maximum inhibitory action against 5-LOX and PGE2 production. The compound 6b-v is found to act by disrupting the redox cycle of the 5-LOX enzyme, and its activity is comparable to that of the commercial drug, Zileuton. The activity of the other compound 6c-i is comparable to a drug in clinical trials, Licofelone, and it has been found to inhibit the mRNA expression of mPGES1 predominantly. It also arrests the HeLa cells in the S and G2/M phases of the cell cycle indicating anticancer activity. Also, compounds, 6b-iv and 6b-viii inhibit both the LT & PG pathways in the inflammation cascade. Presence of iodine in the phenyl ring appears to favour the inhibition of 5-LOX whereas chlorine favours the inhibition of PGE2 production. These leads could be further optimized and developed as drugs against inflammation and cancer.

Tyrosine-derived stimuli responsive, fluorescent amino acids

A series of fluorescent unnatural amino acids (UAAs) bearing stilbene and meta-phenylenevinylene (m-PPV) backbone have been synthesized and their optical properties were studied. These novel UAAs were derived from protected diiodo-l-tyrosine using palladi